New pill aims to stop nausea and vomiting from popular Weight-Loss drugs
NCT ID NCT06500429
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 31 times
Summary
This study tested an experimental oral medication, NG101, to see if it could reduce gastrointestinal side effects (like nausea and vomiting) caused by GLP-1 agonist injections, such as semaglutide. 120 healthy adults with a BMI between 22 and 35 took either NG101 or a placebo for five days, along with a single injection of semaglutide. The goal was to measure how long and how severe any stomach-related side effects lasted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.